Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2019 Business and Financial Update on March 18, 2020
BRIDGEWATER, N.J., March 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 fourth quarter and full year financial results on Wednesday, March 18, 2020, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Wednesday, March 18, 2020 | |
| Time | 4:30 p.m. ET | |
| Toll free (U.S.) | (866) 672-5029 | |
| International | (409) 217-8312 | |
| Webcast (live and replay) | under the “Investor & News” section |
The webcast will be archived for 30 days at the aforementioned URL.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E:
